Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04369183

Rituximab for Refractory or Relapsed Focal Segmental Glomerulosclerosis or Minimal Change Disease

Focal Segmental Glomerulosclerosis Clinical Trial

Official title:
Efficacy and Safety of Rituximab in Adult Patients With Refractory or Relapsed Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

Clinical Trial Summary

Various studies have been conducted to identify effective treatment strategies for primary focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) so far. In the light of these studies, corticosteroids and calcineurin inhibitors have been the treatment of choice and mycophenolic acid derivatives have been seen as a second line agent. However, treatment options in refractory or relapsed cases are still under debate. Recently, rituximab has become an alternative in those patients. Therefore, a study based on registry data was conducted to evaluate the efficacy and safety of rituximab in adult patients suffering from a relapsed or refractory primary FSGS or MCD.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04369183
Study type Observational
Source Istanbul University
Contact
Status Completed
Phase
Start date September 1, 2019
Completion date October 31, 2020
View Details
See also
  Status Clinical Trial Phase
Completed NCT02585804 - Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects Phase 4
Terminated NCT01129557 - Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease Phase 4
Not yet recruiting NCT00956059 - Therapeutic Effect of Low-dose Prednisone Combined With MMF and FK506 in Focal Segmental Glomerulosclerosis N/A
Recruiting NCT05588063 - taVNS for FRNS in Children N/A
Recruiting NCT05583942 - A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS) N/A
Recruiting NCT02896270 - Valproic Acid for Idiopathic Nephrotic Syndrome Phase 2/Phase 3
Completed NCT01113385 - Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome N/A
Terminated NCT00883636 - Cardiomyopathy in Steroid-resistant Nephrotic Syndrome: Impact of Focal Segmental Glomerulosclerosis N/A
Completed NCT04009668 - Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease Phase 2
Terminated NCT03703908 - A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome Phase 2
Completed NCT03649152 - Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan Phase 2
Recruiting NCT06065852 - National Registry of Rare Kidney Diseases
Completed NCT00255398 - Kidney Disease Biomarkers
Active, not recruiting NCT05441826 - Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS) Phase 2
Recruiting NCT02235857 - Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children N/A
Recruiting NCT05942625 - A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects Phase 1
Recruiting NCT02382874 - Allogenic AD-MSC Transplantation in Idiopathic Nephrotic Syndrome (Focal Segmental Glomerulosclerosis) Phase 1
Completed NCT00464321 - Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS Phase 1
Completed NCT03536754 - A Study of CCX140-B in Subjects With FSGS Phase 2
Recruiting NCT03929887 - KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis